Annual CFI
-$53.58 M
-$108.47 M-197.60%
30 September 2023
Summary:
Enanta Pharmaceuticals annual cash flow from investing activities is currently -$53.58 million, with the most recent change of -$108.47 million (-197.60%) on 30 September 2023. During the last 3 years, it has fallen by -$90.57 million (-244.84%). ENTA annual CFI is now -197.60% below its all-time high of $54.90 million, reached on 30 September 2022.ENTA Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$6.34 M
-$64.97 M-110.82%
30 June 2024
Summary:
Enanta Pharmaceuticals quarterly cash flow from investing activities is currently -$6.34 million, with the most recent change of -$64.97 million (-110.82%) on 30 June 2024. Over the past year, it has dropped by -$18.18 million (-153.61%). ENTA quarterly CFI is now -108.73% below its all-time high of $72.68 million, reached on 30 September 2021.ENTA Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$51.00 M
+$139.40 M+157.69%
30 June 2024
Summary:
Enanta Pharmaceuticals TTM cash flow from investing activities is currently $51.00 million, with the most recent change of +$139.40 million (+157.69%) on 30 June 2024. Over the past year, it has increased by +$104.58 million (+195.18%). ENTA TTM CFI is now -59.13% below its all-time high of $124.78 million, reached on 31 March 2023.ENTA TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENTA Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -153.6% | +195.2% |
| 3 y3 years | -244.8% | -108.7% | +37.9% |
| 5 y5 years | +38.2% | +87.8% | +158.8% |
ENTA Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -197.6% | at low | -108.7% | +95.7% | -59.1% | +150.9% |
| 5 y | 5 years | -197.6% | +38.2% | -108.7% | +95.7% | -59.1% | +149.5% |
| alltime | all time | -197.6% | +39.2% | -108.7% | +95.7% | -59.1% | +143.0% |
Enanta Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$6.34 M(-110.8%) | $51.00 M(-157.7%) |
| Mar 2024 | - | $58.62 M(-546.9%) | -$88.41 M(-11.8%) |
| Dec 2023 | - | -$13.12 M(-210.8%) | -$100.26 M(+87.1%) |
| Sept 2023 | -$53.58 M(-197.6%) | $11.84 M(-108.1%) | -$53.58 M(+44.1%) |
| June 2023 | - | -$145.75 M(-411.7%) | -$37.18 M(-129.8%) |
| Mar 2023 | - | $46.77 M(+39.3%) | $124.78 M(+190.4%) |
| Dec 2022 | - | $33.57 M(+18.9%) | $42.97 M(-21.7%) |
| Sept 2022 | $54.90 M(+48.4%) | $28.23 M(+74.1%) | $54.90 M(-44.7%) |
| June 2022 | - | $16.22 M(-146.3%) | $99.35 M(+152.0%) |
| Mar 2022 | - | -$35.05 M(-177.0%) | $39.42 M(-60.6%) |
| Dec 2021 | - | $45.50 M(-37.4%) | $99.94 M(+170.2%) |
| Sept 2021 | $36.99 M(+86.5%) | $72.68 M(-266.3%) | $36.99 M(-211.5%) |
| June 2021 | - | -$43.70 M(-271.7%) | -$33.19 M(-189.0%) |
| Mar 2021 | - | $25.46 M(-245.9%) | $37.30 M(-5.8%) |
| Dec 2020 | - | -$17.45 M(-796.7%) | $39.59 M(+99.6%) |
| Sept 2020 | $19.83 M(-122.9%) | $2.50 M(-90.6%) | $19.83 M(-156.8%) |
| June 2020 | - | $26.78 M(-3.5%) | -$34.88 M(-54.4%) |
| Mar 2020 | - | $27.75 M(-174.6%) | -$76.51 M(-25.7%) |
| Dec 2019 | - | -$37.20 M(-28.7%) | -$102.93 M(+18.8%) |
| Sept 2019 | -$86.66 M(+144.8%) | -$52.21 M(+251.6%) | -$86.66 M(+104.4%) |
| June 2019 | - | -$14.85 M(-1223.1%) | -$42.41 M(-28.2%) |
| Mar 2019 | - | $1.32 M(-106.3%) | -$59.02 M(+9.5%) |
| Dec 2018 | - | -$20.93 M(+163.3%) | -$53.88 M(+52.2%) |
| Sept 2018 | -$35.40 M | -$7.95 M(-74.7%) | -$35.40 M(-16.4%) |
| June 2018 | - | -$31.46 M(-587.3%) | -$42.35 M(+1209.6%) |
| Mar 2018 | - | $6.46 M(-363.8%) | -$3.23 M(-59.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | - | -$2.45 M(-83.6%) | -$7.88 M(+72.5%) |
| Sept 2017 | -$4.57 M(-89.5%) | -$14.90 M(-294.6%) | -$4.57 M(-209.3%) |
| June 2017 | - | $7.66 M(+324.0%) | $4.18 M(-112.0%) |
| Mar 2017 | - | $1.81 M(+108.8%) | -$34.90 M(-6.1%) |
| Dec 2016 | - | $865.00 K(-114.1%) | -$37.17 M(-14.9%) |
| Sept 2016 | -$43.66 M(-50.5%) | -$6.15 M(-80.4%) | -$43.66 M(+30.7%) |
| June 2016 | - | -$31.43 M(+6776.8%) | -$33.42 M(-640.5%) |
| Mar 2016 | - | -$457.00 K(-91.9%) | $6.18 M(-106.1%) |
| Dec 2015 | - | -$5.63 M(-237.4%) | -$100.84 M(+14.4%) |
| Sept 2015 | -$88.19 M(<-9900.0%) | $4.10 M(-49.9%) | -$88.19 M(+6.2%) |
| June 2015 | - | $8.17 M(-107.6%) | -$83.07 M(-29.9%) |
| Mar 2015 | - | -$107.48 M(-1629.6%) | -$118.56 M(-2020.0%) |
| Dec 2014 | - | $7.03 M(-23.7%) | $6.17 M(+1142.5%) |
| Sept 2014 | $497.00 K(-100.7%) | $9.21 M(-133.7%) | $497.00 K(-103.0%) |
| June 2014 | - | -$27.31 M(-258.4%) | -$16.35 M(-56.1%) |
| Mar 2014 | - | $17.25 M(+1178.6%) | -$37.26 M(-47.0%) |
| Dec 2013 | - | $1.35 M(-117.7%) | -$70.37 M(+1.7%) |
| Sept 2013 | -$69.22 M(+283.7%) | -$7.64 M(-84.2%) | -$69.22 M(+32.3%) |
| June 2013 | - | -$48.22 M(+204.1%) | -$52.34 M(+207.8%) |
| Mar 2013 | - | -$15.86 M(-734.6%) | -$17.00 M(-24.4%) |
| Dec 2012 | - | $2.50 M(-73.0%) | -$22.49 M(+24.7%) |
| Sept 2012 | -$18.04 M(+2.0%) | $9.24 M(-171.7%) | -$18.04 M(-33.9%) |
| June 2012 | - | -$12.89 M(-39.6%) | -$27.28 M(+89.5%) |
| Mar 2012 | - | -$21.35 M(-407.1%) | -$14.39 M(-307.1%) |
| Dec 2011 | - | $6.95 M | $6.95 M |
| Sept 2011 | -$17.68 M(-1163.3%) | - | - |
| Sept 2010 | $1.66 M | - | - |
FAQ
- What is Enanta Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals quarterly CFI year-on-year change?
- What is Enanta Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals TTM CFI year-on-year change?
What is Enanta Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of ENTA is -$53.58 M
What is the all time high annual CFI for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high annual cash flow from investing activities is $54.90 M
What is Enanta Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of ENTA is -$6.34 M
What is the all time high quarterly CFI for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high quarterly cash flow from investing activities is $72.68 M
What is Enanta Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, ENTA quarterly cash flow from investing activities has changed by -$18.18 M (-153.61%)
What is Enanta Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of ENTA is $51.00 M
What is the all time high TTM CFI for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high TTM cash flow from investing activities is $124.78 M
What is Enanta Pharmaceuticals TTM CFI year-on-year change?
Over the past year, ENTA TTM cash flow from investing activities has changed by +$104.58 M (+195.18%)